Evidence map›Paper›PMID 29440311›Full record

ArticleMolecular and cellular biology2018

Heritable, Allele-Specific Chromosomal Looping between Tandem Promoters Specifies Promoter Usage of

Xichuan Li, Zhenzhen Lin, Hao Wang, Dan Zhao, Xing Xu, Yiliang Wei, Xiaoting Li, Xiaobo Li, Yougui Xiang, Lance S Terada and 1 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular and cellular biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Xichuan Li *Department of Immunology, Tianjin Key Laboratory of Medical Epigenetics, Collaborative Innovation Center of Tianjin for Medical Epigenetics, Tianjin Medical University, Tianjin, China.
Zhenzhen Lin *Department of Immunology, Tianjin Key Laboratory of Medical Epigenetics, Collaborative Innovation Center of Tianjin for Medical Epigenetics, Tianjin Medical University, Tianjin, China.
Hao Wang *Department of Immunology, Tianjin Key Laboratory of Medical Epigenetics, Collaborative Innovation Center of Tianjin for Medical Epigenetics, Tianjin Medical University, Tianjin, China.
Dan ZhaoDepartment of Immunology, Tianjin Key Laboratory of Medical Epigenetics, Collaborative Innovation Center of Tianjin for Medical Epigenetics, Tianjin Medical University, Tianjin, China.
Xing XuDepartment of Immunology, Tianjin Key Laboratory of Medical Epigenetics, Collaborative Innovation Center of Tianjin for Medical Epigenetics, Tianjin Medical University, Tianjin, China.
Yiliang WeiDepartment of Immunology, Tianjin Key Laboratory of Medical Epigenetics, Collaborative Innovation Center of Tianjin for Medical Epigenetics, Tianjin Medical University, Tianjin, China.
Xiaoting LiDepartment of Immunology, Tianjin Key Laboratory of Medical Epigenetics, Collaborative Innovation Center of Tianjin for Medical Epigenetics, Tianjin Medical University, Tianjin, China.
Xiaobo LiDepartment of Immunology, Tianjin Key Laboratory of Medical Epigenetics, Collaborative Innovation Center of Tianjin for Medical Epigenetics, Tianjin Medical University, Tianjin, China.
Yougui XiangDepartment of Immunology, Tianjin Key Laboratory of Medical Epigenetics, Collaborative Innovation Center of Tianjin for Medical Epigenetics, Tianjin Medical University, Tianjin, China.
Lance S TeradaDepartment of Internal Medicine, Division of Pulmonary and Critical Care, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Zhe LiuDepartment of Immunology, Tianjin Key Laboratory of Medical Epigenetics, Collaborative Innovation Center of Tianjin for Medical Epigenetics, Tianjin Medical University, Tianjin, China zheliu@tmu.edu.cn.
Tianjin Medical University Cancer Institute and Hospital · CNTianjin Medical University · CNThe University of Texas Southwestern Medical Center · US

Funding

(PQ1) Epigenetic effects of the premalignant fieldR01CA208620 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI TERADA, LANCE S · 2016 to 2020
$1.9M
NCI NIH HHS R01 CA208620
6 · The paper itself

Abstract

One-half of the genes in the human genome contain alternative promoters, some of which generate products with opposing functions. Aberrant silencing or activation of such alternative promoters is associated with multiple diseases, including cancer, but little is known regarding the molecular mechanisms that control alternative promoter choice. The

Indexed as

AllelesChromatinEndothelial CellsGene Expression RegulationHumansHuman Umbilical Vein Endothelial CellsPrimary Cell CulturePromoter Regions, GeneticSrc Homology 2 Domain-Containing, Transforming Protein 1Transcriptional ActivationChromatinSHC1 protein, humanSrc Homology 2 Domain-Containing, Transforming Protein 1allele-specific transcriptionalternative promoter interactiongene silencingSHC1

Identifiers

PMID29440311
PMCPMC5902595
OpenAlexW2804859903

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.